Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A systematic review and meta-analysis

Journal of Invasive Cardiology

Volumn 22, Issue 6, 2010, Pages 278-282

  Hansen, Peter Riis ^a   Iversen, Allan ^b   Abdulla, Jawdat ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; FOLLOW UP; HUMAN; INTRACORONARY INFUSION; META ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY VESSELS; DRUG ADMINISTRATION ROUTES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; PLATELET AGGREGATION INHIBITORS;

EID: 77953169406     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Silber S, Albertsson P, Aviles FF et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-847.
2. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Circulation 2008;117:261-295.
3. Kereiakes DJ. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function. Rev Cardiovasc Med 2006;7(Suppl 4): S3-S11.
4. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin abtiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
5. Coller BS. Monitoring platelet GP IIb/IIIa antagonist activity. Circulation 1998;97:5-9.
6. Gibson CM, Jennings LK, Murphy SA et al. Association between platelet receptor occupancy after eptifibatide (Integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment elevation myocardial infarcion: An INTEGRITI (Integrillin and Tenecteplase in Acute Myocardial Infaction) substudy. Circulation 2004;110:679-684.
7. De Prado AP, Fernández-Vásquez F, Cuellas JC, et al. Association between the level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2006;97:798-803.
8. Romagnoli E, Burzotta F, Trani C et al. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007;23:57-63.
9. Sharma S, Makkar R, Lardizabal J. Intracoronary administration of abciximab during percutaneous interventions: Should this approach be the routine and preferred approach? J Cardiovasc Pharmacol Ther 2006;11:136-141.
10. Patel SS, Rana H, Mascarenhas D A N. Intracoronary abciximab use in patients undergoing PCI at a community hospital: A single operation experience. J Cardiovasc Pharmacol Ther 2008;13:89-93.
11. Romagnoli E, Burzotta F, Trani C, et al. Angiographic evaluation of the effects of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 2005;105:250-255.
12. Wöhrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003;107:1840-1843.
13. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 2004;61:31-34.
14. Bellandi F, Maiolli M, Gallopin M, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004;62:186-192.
15. Galache Osuna JG, Sánchez-Rubio J, Calvo I, et al. Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomised controlled trial. Rev Esp Cardiol 2006;59:567-574.
16. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2008;118:49-57.
17. Bertrand OF, Rodés-Cabau J, Larose E, et al. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial. Int J Cardiol 2009;136:165-170.
18. Dominguez-Rodriguez A, Abreu-Gonzales P, Avanzas P, et al. Intracoronary versus intravenous abciximab administration in patients with ST-elevations myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention - Effects on soluble CD-40 ligand concentrations. Atherosclerosis 2009;206:523-527.
19. Iversen A, Abildgaard U, Galløe A, et al. Intracoronary compared to intravenous bolus Abciximab during primary percutaneous coronary intervention in STEMI patients reduces 30-days mortality and target vessel revascularization. A randomized trial. (Submitted).
20. Bertrand OF, De Larochellière R, Rodés-Cabau J, et al. A randomised study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab colus and infusion after transradial coronary stent implantation. Circulation 2006;114:2636-2643.
21. Bertrand OF, Rodés-Cabau J, Larose E, et al. One year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomised Early discharge after Transradial Stenting of Coronary Arteries (EASY) study. Am Heart J 2008;156:135-140.
22. Ernst N M S J, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:1187-1193.
23. Kastrati A, Mehilli J, Schühlen H et al. A clinical trial of abciximab in elective percutaneous intervention after pre-treatment with clopidogrel. N Engl J Med 2004;350:232-238. (Pubitemid 38071801)
24. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: The ISAR-REACT 2 randomized trial. JAMA 2006;295:1531-1538.
25. Mehilli J, Kastrati A, Schultz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary inter-vention after clopidogrel loading. A randomised double-blind trial. Circulation 2009;119:1933-1940.
26. De Luca G, Naverese E, Marino P. Risk profile and benefits from GP IIb/IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: A meta-regression analysis of randomised trials. Eur Heart J 2009;30:2705-2713.
27. Maioli M, Bellandi F, Leoncini M, et al. Randomised early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI trial). J Am Coll Cardiol 2007;49:1517-1524.
28. De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: An individual patient data meta-analysis. Heart 2008;94:1548-1558.
29. Alexander D, Mann N, Fang-Shu O, et al. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). Am J Cardiol 2008;102:1335-1340.
30. Pinto DS, Kirtane AJ, Ruocco NA, et al. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. Am J Cardiol 2005;96:1494-1497.
31. Gurm HS, Smith DE, Collins JS, et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008;51:529-535.
32. Wu TG, Huang WG, Wei JR, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J 2008;72:1605-1609.
33. Gu YL, Fokkema ML, Kampinga MA, et al. Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration. Trials 2009;10:90.
34. Sardella G, Sangiorgi GM, Mancone M, et al. A multicenter randomized study to evaluate intracoronary abciximab with the Clear Way catheter to improve outcomes with lysis (IC ClearLy): Trial study design and rationale. J Cardiovasc Med (Hagerstown) 2009 Nov. 13. [Epub ahead of print].